Insightec: Revolutionizing Healthcare with Focused Ultrasound Technology
June 25, 2024, 3:35 am
Location: Israel, Haifa District, Tirat Karmel
Employees: 201-500
Founded date: 1999
Total raised: $661.9M
Insightec, a healthcare company at the forefront of using focused ultrasound to revolutionize patient care, recently secured a whopping $150 million in equity financing. This funding round, led by Fidelity Management & Research Company, Nexus Neurotech Ventures, and Ally Bridge Group, signifies a major milestone for the company's mission to transform the treatment of movement disorders like essential tremor and Parkinson's disease.
With over 160 systems installed globally, Insightec's Exablate Prime platform harnesses the power of sound waves, guided by MRI technology, to provide incisionless and immediate relief to patients suffering from these debilitating conditions. The company's innovative approach has already been utilized in nearly 20,000 commercial applications, showcasing the tangible impact of their cutting-edge technology.
In a landscape where traditional treatment options often fall short, Insightec's commitment to pushing the boundaries of medical innovation is truly commendable. By partnering with leading academic and medical institutions, the company is actively exploring new applications in the neuroscience space, paving the way for groundbreaking advancements in patient care.
CEO and chairman of the board, Maurice R Ferré, M.D., expressed gratitude for the unwavering support of both new and existing investors, highlighting the pivotal role this financing will play in expanding access to incisionless neurosurgery for patients in need. With offices in Haifa, Israel, Miami, Dallas, Shanghai, and Tokyo, Insightec's global reach underscores their dedication to making a meaningful difference in the lives of individuals affected by movement disorders.
As Insightec continues to push the boundaries of what is possible in healthcare, their innovative approach to utilizing focused ultrasound technology serves as a beacon of hope for patients and healthcare providers alike. With a clear vision and unwavering commitment to transforming patient care, Insightec is poised to lead the charge in revolutionizing the treatment of movement disorders for years to come.
With over 160 systems installed globally, Insightec's Exablate Prime platform harnesses the power of sound waves, guided by MRI technology, to provide incisionless and immediate relief to patients suffering from these debilitating conditions. The company's innovative approach has already been utilized in nearly 20,000 commercial applications, showcasing the tangible impact of their cutting-edge technology.
In a landscape where traditional treatment options often fall short, Insightec's commitment to pushing the boundaries of medical innovation is truly commendable. By partnering with leading academic and medical institutions, the company is actively exploring new applications in the neuroscience space, paving the way for groundbreaking advancements in patient care.
CEO and chairman of the board, Maurice R Ferré, M.D., expressed gratitude for the unwavering support of both new and existing investors, highlighting the pivotal role this financing will play in expanding access to incisionless neurosurgery for patients in need. With offices in Haifa, Israel, Miami, Dallas, Shanghai, and Tokyo, Insightec's global reach underscores their dedication to making a meaningful difference in the lives of individuals affected by movement disorders.
As Insightec continues to push the boundaries of what is possible in healthcare, their innovative approach to utilizing focused ultrasound technology serves as a beacon of hope for patients and healthcare providers alike. With a clear vision and unwavering commitment to transforming patient care, Insightec is poised to lead the charge in revolutionizing the treatment of movement disorders for years to come.